The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator–activated receptor-γ
Open accessAbstract
5-aminosalicylic acid (5-ASA) is an antiinflammatory drug widely used in the treatment of inflammatory bowel diseases. It is known to inhibit the production of cytokines and inflammatory mediators, but the mechanism underlying the intestinal effects of 5-ASA remains unknown. Based on the common activities of peroxisome proliferator–activated receptor-γ (PPAR-γ) ligands and 5-ASA, we hypothesized that this nuclear receptor mediates 5-ASA therapeutic action. To test this possibility, colitis was induced in heterozygous PPAR-γ+/− mice and their wild-type littermates, which were then treated with 5-ASA. 5-ASA treatment had a beneficial effect on colitis only in wild-type and not in heterozygous mice. In epithelial cells, 5-ASA increased PPAR-γ expression, promoted its translocation from the cytoplasm to the nucleus, and induced a modification of its conformation permitting the recruitment of coactivators and the activation of a peroxisome-proliferator response element–driven gene. Validation of these results was obtained with organ cultures of human colonic biopsies. These data identify PPAR-γ as a target of 5-ASA underlying antiinflammatory effects in the colon.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Massagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,529
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Validation of the general purpose tripos 5.2 force field
Clark, M., Cramer, R. D., & Van Opdenbosch, N. (1989) · Journal of Computational Chemistry · doi:10.1002/jcc.540100804 · Cited by 2,812
Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ
Nolte, R. T., Wisely, G. B., Westin, S., Cobb, J. E., Lambert, M. H., Kurokawa, R., Rosenfeld, M. G., Willson, T. M., Glass, C. K., & Milburn, M. V. (1998) · Nature · doi:10.1038/25931 · Cited by 1,958
PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.
Spiegelman, B. M. (1998) · Diabetes · doi:10.2337/diabetes.47.4.507 · Cited by 1,730
Wang, R., Lai, L., & Wang, S. (2002) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1016357811882 · Cited by 1,191
Cited by
Ungaro, R., Mehandru, S., Allen, P. B., Peyrin-Biroulet, L., & Colombel, J.-F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32126-2 · Cited by 3,531
Self-citationFat and Beyond: The Diverse Biology of PPARγ
Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085
Kaser, A., Zeissig, S., & Blumberg, R. S. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101225 · Cited by 1,806
Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis
Sartor, R. B. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0528 · Cited by 1,757
International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors
Michalik, L., Auwerx, J., Berger, J. P., Chatterjee, V. K., Glass, C. K., Gonzalez, F. J., Grimaldi, P. A., Kadowaki, T., Lazar, M. A., O’Rahilly, S., et al. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.5 · Cited by 1,000
Self-citationColonocyte metabolism shapes the gut microbiota
Litvak, Y., Byndloss, M. X., & Bäumler, A. J. (2018) · Science · doi:10.1126/science.aat9076 · Cited by 764
Current and emerging therapeutic targets for IBD
Neurath, M. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.208 · Cited by 691
PPARs at the crossroads of lipid signaling and inflammation
Wahli, W., & Michalik, L. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.05.001 · Cited by 675
Self-citationNew IBD genetics: common pathways with other diseases
Lees, C. W., Barrett, J. C., Parkes, M., & Satsangi, J. (2011) · Gut · doi:10.1136/gut.2009.199679 · Cited by 635
Immunological pathogenesis of inflammatory bowel disease
Lee, S. H., Kwon, J. E., & Cho, M.-L. (2018) · Intestinal Research · doi:10.5217/ir.2018.16.1.26 · Cited by 575
Farraye, F. A., Odze, R. D., Eaden, J., & Itzkowitz, S. H. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.035 · Cited by 494
The Intestinal Immune System in Obesity and Insulin Resistance
Winer, D. A., Luck, H., Tsai, S., & Winer, S. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.01.003 · Cited by 475
PPARγ as a new therapeutic target in inflammatory bowel diseases
Dubuquoy, L., Rousseaux, C., Thuru, X., Peyrin-Biroulet, L., Romano, O., Chavatte, P., Chamaillard, M., & Desreumaux, P. (2006) · Gut · doi:10.1136/gut.2006.093484 · Cited by 450
Self-citationRisk for colorectal cancer in ulcerative colitis: Changes, causes and management strategies
Lakatos, P. L., & Lakatos, L. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3937 · Cited by 442
The microbiome and gut homeostasis
Lee, J.-Y., Tsolis, R. M., & Bäumler, A. J. (2022) · Science · doi:10.1126/science.abp9960 · Cited by 428
Regulation of Obesity-Related Insulin Resistance with Gut Anti-inflammatory Agents
Luck, H., Tsai, S., Chung, J., Clemente-Casares, X., Ghazarian, M., Revelo, X. S., Lei, H., Luk, C. T., Shi, S. Y., Surendra, A., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.03.001 · Cited by 368
Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis
Ford, A. C., Achkar, J.-P., Khan, K. J., Kane, S. V., Talley, N. J., Marshall, J. K., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.67 · Cited by 295
Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease
Akobeng, A. K., Zhang, D., Gordon, M., & MacDonald, J. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003715.pub3 · Cited by 289
Bifidobacterium Longum: Protection against Inflammatory Bowel Disease
Yao, S., Zhao, Z., Wang, W., & Liu, X. (2021) · Journal of Immunology Research · doi:10.1155/2021/8030297 · Cited by 255
The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR)
Peraza, M. A., Burdick, A. D., Marin, H. E., Gonzalez, F. J., & Peters, J. M. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj062 · Cited by 254
SAMP1/YitFc mouse strain: A spontaneous model of Crohnʼs disease-like ileitis
Pizarro, T. T., Pastorelli, L., Bamias, G., Garg, R. R., Reuter, B. K., Mercado, J. R., Chieppa, M., Arseneau, K. O., Ley, K., & Cominelli, F. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21638 · Cited by 192
Targeting Peroxisome Proliferator-Activated Receptors (PPARs): Development of Modulators
Pirat, C., Farce, A., Lebègue, N., Renault, N., Furman, C., Millet, R., Yous, S., Speca, S., Berthelot, P., Desreumaux, P., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm101360s · Cited by 198
CORINALDESI, R., STANGHELLINI, V., CREMON, C., GARGANO, L., COGLIANDRO, R. F., DE GIORGIO, R., BARTESAGHI, G., CANOVI, B., & BARBARA, G. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04041.x · Cited by 131
Ondrey, F. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0326 · Cited by 126
Healthy hosts rule within: ecological forces shaping the gut microbiota
Byndloss, M. X., Pernitzsch, S. R., & Bäumler, A. J. (2018) · Mucosal Immunology · doi:10.1038/s41385-018-0010-y · Cited by 109
Nitrated oleic acid up-regulates PPARγ and attenuates experimental inflammatory bowel disease
Borniquel, S., Jansson, E. Å., Cole, M. P., Freeman, B. A., & Lundberg, J. O. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.11.014 · Cited by 92
“5-ASA is commonly used in the treatment of IBD and has recently been suggested to act via activation of PPARγ [6].”
InfluentialPPAR-γ Activation As an Anti-inflammatory Therapy for Respiratory Virus Infections
Bassaganya-Riera, J., Song, R., Roberts, P. C., & Hontecillas, R. (2010) · Viral Immunology · doi:10.1089/vim.2010.0016 · Cited by 83
Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
P. Menendez-Gutierrez, M., Roszer, T., & Ricote, M. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612799436669 · Cited by 62
Saijo, F., Milsom, A. B., Bryan, N. S., Bauer, S. M., Vowinkel, T., Ivanovic, M., Andry, C., Granger, D. N., Rodriguez, J., & Feelisch, M. (2010) · Nitric Oxide · doi:10.1016/j.niox.2009.11.009 · Cited by 51
Tuteja, A. K., Fang, J. C., Al-Suqi, M., Stoddard, G. J., & Hale, D. C. (2012) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2012.694903 · Cited by 41
Gardiner, L.-J., Carrieri, A. P., Bingham, K., Macluskie, G., Bunton, D., McNeil, M., & Pyzer-Knapp, E. O. (2022) · PLOS ONE · doi:10.1371/journal.pone.0263248 · Cited by 36
“The mechanisms of action of 5-ASA, prednisolone and BIRB796 have all been shown to interact with TNFα signalling via peroxisome proliferator-activated receptor gamma (PPARγ) [14], nuclear factor kappa light chain enhancer of activated B cells (NF-κB) [15] and mitogen activated protein kinase (MAPK) [16], respectively.”
BackgroundInfluential
Metadata
- Authors
- Rousseaux, C., Lefebvre, B., Dubuquoy, L., Lefebvre, P., Romano, O., Auwerx, J., Metzger, D., Wahli, W., Desvergne, B., Naccari, G. C., Chavatte, P., Farce, A., Bulois, P., Cortot, A., Colombel, J. F., & Desreumaux, P.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2005-04-11
- Volume
- 201
- Issue
- 8
- Pages
- 1205-1215
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2137537116
- Cited by
- 526
- References
- 55
- FWCI
- 10.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.